Lung cancer patients harbouring epidermal growth factor receptor mutation

Introduction: EGFR mutation status is associated with the response to targeted therapy and survival.Data regarding this subject in the Portuguese population is scarce. Methods: 333 NSCLCs patients were tested for EGFR mutations, between 2010 and 2013,and patients with EGFRmutation were included. Clinical, pathological parameters, treatment and survival were analysed. Results: EGFR mutations (exons 18 to 21) were detected in 61 (18,3%)of 333NSCLCs. Patients with EGFR mutation included 39 female, median age of 67,2 years, 11% smokers,21,8%ex-smokers and 67,3% non-smokers.The majority (91,8%) were adenocarcinoma. Thirty-one(31,1%)patientshad an exon 19 deletion, 20 (32,7%) had an exon 21 mutation, 6 (9,8%) had an exon 20 mutation and 4 (6,5%) had an exon 18 mutation.For the patients with stage IV disease themedian overall survival was12 months for the 19EGFR mutation and 9 months for the 21 EGFR mutation. For the rare mutations, the overall survival was 21 months and 1 month, respectively for the 18 and20exons. The overall survival was not different according to the mutation exon (p>0,05).In thestage IV, the overall survival was not significantly affected (p>0,05) by the first line treatment, conventional chemotherapy(n=11)versus tyrosine kinase inhibitors (n=31). The overall survival was significantly longer for the 19 and 21 exons than 18 and 20 exons (p Conclusion: In this population, EGFR mutation frequency was 18,3%. The most frequent mutations were in accordance with literature. Among the rare mutations found,exon 20 seems to be the more aggressive type, however without a significant statistical difference.Theoverall survival was not influenced by the choice of first line therapy.